Amgen, Cytokinetics heart drug fails to add puff

|About: Amgen Inc. (AMGN)|By:, SA News Editor

An intravenous version of Amgen's (AMGN) and Cytokinetics' (CYTK -17.3%) Omecamtiv Mecarbil treatment missed its target of improving shortness of breath in heart-failure patients in a Phase II trial.

However, Amgen plans to continue testing an oral version in a separate Phase II study. The companies will use the combined results to determine whether to take Omecamtiv Mecarbil into Phase III testing. (PR)